Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.
作者： Alessio Imperiale , Adrien Latgé , Frédérique Schaff-Wendling , Bernard Goichot , Jean-Emmanuel Kurtz
DOI: 10.1097/RLU.0000000000002231
关键词:
摘要: We report the results of serial F-FDG PET/CT investigations in a 49-year-old woman presenting with an advanced cecal high-grade neuroendocrine carcinoma harboring somatic BRAF mutation. Patient was refractory to standard chemotherapy regimen showing life-threatening hyperlactatemia. Early after beginning BRAF-MEK therapy (dabrafenib and trametinib), impressive improvement imaging achieved. The pathological uptake primary tumor as well nodal, hepatic, bone metastases drastically decreased. Moreover, reduction total lesion glycolysis on images strictly related extraordinary patient clinical response lactic acid level normalization.
sci-hub.se 参考文章(9)
Halfdan Sorbye, Jonathan Strosberg, Eric Baudin, David S. Klimstra, James C. Yao, Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. ,vol. 120, pp. 2814- 2823 ,(2014) , 10.1002/CNCR.28721
A L T Imholz, M N Gerding, R de Groot, R A Sprenger, Type B lactic acidosis in solid malignancies. Netherlands Journal of Medicine. ,vol. 69, pp. 120- 123 ,(2011)
Joanne R. Doherty, John L. Cleveland, Targeting lactate metabolism for cancer therapeutics Journal of Clinical Investigation. ,vol. 123, pp. 3685- 3692 ,(2013) , 10.1172/JCI69741
Grant A. McArthur, Igor Puzanov, Ravi Amaravadi, Antoni Ribas, Paul Chapman, Kevin B. Kim, Jeffrey A. Sosman, Richard J. Lee, Keith Nolop, Keith T. Flaherty, Jason Callahan, Rodney J. Hicks, Marked, Homogeneous, and Early [18F]Fluorodeoxyglucose–Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma Journal of Clinical Oncology. ,vol. 30, pp. 1628- 1634 ,(2012) , 10.1200/JCO.2011.39.1938
H Sorbye, SFAU Welin, Seppo Wang Langer, Lene Weber Vestermark, Nanna Holt, P Osterlund, S Dueland, E Hofsli, MG Guren, K Ohrling, E Birkemeyer, E Thiis-Evensen, Matteo Biagini, H Gronbaek, LM Soveri, IH Olsen, Birgitte Federspiel, J Assmus, ET Janson, U Knigge, None, Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study Annals of Oncology. ,vol. 24, pp. 152- 160 ,(2013) , 10.1093/ANNONC/MDS276
Bruno Conte, Ben George, Michael Overman, Jeannelyn Estrella, Zhi-Qin Jiang, Amir Mehrvarz Sarshekeh, Renata Ferrarotto, Paulo M. Hoff, Asif Rashid, James C. Yao, Scott Kopetz, Arvind Dasari, High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients Clinical Colorectal Cancer. ,vol. 15, ,(2016) , 10.1016/J.CLCC.2015.12.007
Charny Park, Sang Yun Ha, Seung Tae Kim, Hee Cheol Kim, Jin Seok Heo, Young Suk Park, Gregory Lauwers, Jeeyun Lee, Kyoung-Mee Kim, Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors Oncotarget. ,vol. 7, pp. 4024- 4035 ,(2016) , 10.18632/ONCOTARGET.6602
Samuel J. Klempner, Bruce Gershenhorn, Phu Tran, Thomas K. Lee, Mark G. Erlander, Kyle Gowen, Alexa B. Schrock, Deborah Morosini, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, Sai-Hong Ignatius Ou, Siraj M. Ali, BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF–MEK Combination Therapy Cancer Discovery. ,vol. 6, pp. 594- 600 ,(2016) , 10.1158/2159-8290.CD-15-1192
Teresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, Harold G. Parkes, Richard Marais, Paul Workman, Martin O. Leach, Mounia Beloueche-Babari, The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells. Molecular Cancer Therapeutics. ,vol. 15, pp. 2987- 2999 ,(2016) , 10.1158/1535-7163.MCT-16-0068